[go: up one dir, main page]

WO2025143788A1 - Composition pour améliorer le métabolisme bioénergétique contenant du kestose - Google Patents

Composition pour améliorer le métabolisme bioénergétique contenant du kestose Download PDF

Info

Publication number
WO2025143788A1
WO2025143788A1 PCT/KR2024/021115 KR2024021115W WO2025143788A1 WO 2025143788 A1 WO2025143788 A1 WO 2025143788A1 KR 2024021115 W KR2024021115 W KR 2024021115W WO 2025143788 A1 WO2025143788 A1 WO 2025143788A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
kestose
energy metabolism
sugar
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/KR2024/021115
Other languages
English (en)
Korean (ko)
Inventor
박세영
사순옥
김고은
류경헌
한정숙
김도현
황환주
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samyang Corp
Original Assignee
Samyang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Corp filed Critical Samyang Corp
Publication of WO2025143788A1 publication Critical patent/WO2025143788A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to a use for promoting energy metabolism or a use for improving energy metabolism reduction, which comprises kestos as an effective ingredient.
  • ATP adenosine triphosphate
  • Creatine has been reported to be effective in stimulating ATP production because it plays a role in anaerobic ATP production during short/intensive exercise via the creatine kinase system. These supplements often fail to achieve the desired increase in ATP production, especially intramuscular ATP production.
  • compositions and methods for increasing energy metabolism and ATP production are known in the art, all or nearly all of them suffer from one or more drawbacks. Accordingly, there still remains a need to provide improved compositions and methods for increasing energy metabolism and ATP production.
  • One example of the present invention is to provide a composition for promoting energy metabolism in an individual, comprising kestos as an active ingredient.
  • Another example of the present invention relates to a composition for promoting adenosine triphosphate (ATP) production in tissues having mitochondria, comprising kestose as an active ingredient, and more particularly, to provide a composition for promoting mitochondrial biogenesis.
  • ATP adenosine triphosphate
  • Another example of the present invention is to provide a composition for promoting protein biosynthesis in mitochondria in tissues having mitochondria, comprising kestose as an active ingredient.
  • Another example of the present invention is to provide a composition for promoting sugar absorption, comprising kestose as an active ingredient.
  • Another aspect of the present invention provides a composition for preventing, improving and/or treating energy metabolism-related diseases, comprising kestose as an active ingredient.
  • Another example of the present invention is to provide a method for enhancing energy metabolism in a subject, comprising the step of administering kestos to a subject in need of enhancing energy metabolism.
  • Another example of the present invention is to provide a method for preventing, improving and/or treating an energy metabolism related disease, comprising the step of administering kestos to a subject in need of prevention, improvement and/or treatment of an energy metabolism related disease.
  • Another example of the present invention provides a use of Kestos for promoting energy metabolism or for preventing, improving and/or treating diseases related to energy metabolism.
  • Another example of the present invention is to provide a use of kestos for preparing a composition for promoting energy metabolism in a subject or a composition for preventing, improving and/or treating a disease related to energy metabolism.
  • enhancing energy metabolism means a process of enhancing energy production, utilization, and storage at the cellular and biological levels, and specifically, may be at least one selected from the group consisting of promoting adenosine triphosphate (ATP) production in tissues having mitochondria (specifically, promoting mitochondrial biogenesis), promoting protein biosynthesis within mitochondria in tissues having mitochondria, promoting insulin secretion, and promoting sugar absorption, but is not limited thereto.
  • ATP adenosine triphosphate
  • composition of the present invention containing kestose as an active ingredient has uses such as promoting bioenergy metabolism, promoting adenosine triphosphate (ATP) production in tissues having mitochondria, promoting protein biosynthesis within mitochondria in tissues having mitochondria, promoting insulin secretion, and promoting sugar absorption.
  • ATP adenosine triphosphate
  • a composition containing Kestos according to the present invention as an active ingredient may be, for example, a pharmaceutical composition or a food composition.
  • a composition containing ketose according to the present invention as an active ingredient can be used to promote energy metabolism in a subject or an individual, and the subject or individual can be a mammal, including a human.
  • the present invention relates to a composition and method for promoting energy metabolism, and more particularly, to a composition for increasing ATP production.
  • the present invention provides a food composition for promoting or improving the energy level of a subject.
  • the composition according to the present invention can substantially increase ATP and energy levels, and in particular, it has been confirmed that the increase in ATP production in muscle tissue is higher, and in particular, it has the effect of promoting ATP and energy levels in muscle cells.
  • Such entities may be mammals, including humans, for example, humans suffering from diseases that reduce intracellular adenosine triphosphate (ATP), humans engaged in excessive physical activity, such as athletes or workers, and humans seeking to increase their energy levels.
  • Other mammals, such as dogs or cats, are also included in the present method.
  • compositions according to the present invention increases the level of ATP within muscle cells, prolongs the time and intensity for which a mammal can exercise, and mammals that do not exercise and mammals that expend higher than normal levels of energy while recovering from physical insults such as trauma, burns and sepsis also benefit from administration of the composition of the present invention.
  • the composition for promoting bioenergy metabolism, the method for promoting energy metabolism in a subject, and/or the method for preventing, improving, and/or treating diseases related to energy metabolism according to the present invention stimulate and promote ATP synthesis in a mammal, and specifically, kestose is orally administered in an amount effective to enhance the energy of the mammal before, during, and after a period of high ATP demand.
  • the subject administered kestose can exercise longer, achieve higher intensities, and subjectively have more energy than a mammal not administered kestose.
  • the present invention provides a method for stimulating ATP synthesis by administering kestose, and provides a kestose-containing composition that is particularly beneficial for mammals experiencing high energy demand or mammals with chronically low energy levels.
  • the above enhancement of energy metabolism can occur in muscle cells or muscle tissue.
  • mitochondrial biogenesis pathway activators activate or increase genes of the pathway. Increase or activation of the mitochondrial biogenesis pathway can be observed by increased activity of genes of the pathway.
  • AMPK senses the amount of energy (ATP) to maintain energy balance and plays a role in activating energy and mitochondrial biogenesis metabolic pathways.
  • SIRT1 small cell lung cancer
  • PGC1 ⁇ peroxisome proliferator-activated receptor gamma coactivator
  • TFAM Mitochondrial transcription factor A
  • NRF1 Nuclear respiratory factor 1
  • IRS-1 Insulin receptor substrate 1
  • Akt MyoD
  • MyoG Myogenin
  • insulin secretion decreases due to a decline in pancreatic beta cell function, or insulin resistance of peripheral tissues such as muscles, liver and blood vessels increases, blood sugar cannot be used as an energy source and is excreted from the body, which leads to various complications. Therefore, it also contributes to promoting energy metabolism by promoting glucose absorption to supply glucose used as an energy source in muscle cells or intestinal cells.
  • the primer sequence information used in performing PCR is shown in Table 1 above, and the results of measuring the expression level of mitochondrial biogenesis promoting factors are shown in Figure 3.
  • the expression levels of AMPK, SIRT1, PGC1 ⁇ , TFAM, and NRF1 were measured to be higher in the group treated with 1-kestose compared to the other groups.
  • Example 3-2 Measurement of protein concentration in mitochondria that generate energy source (ATP) used for energy metabolism in muscle cells (C2C12)
  • Muscle cells (C2C12) passaged more than twice in Example 1 were seeded at a concentration of 5x104 cells/well/mL in a 12-well plate, and the muscle cells were differentiated for 6 days using DMEM containing 2% horse serum in substantially the same manner as in Example 1, and 1-kestose, glucose, or maltose was treated to the muscle cells to react.
  • Mitochondrial isolation kit (Thermo Fisher Scientific; Rockford, IL, USA) was used. Differentiated muscle cells (C2C12) were obtained with a scraper and washed twice with cold PBS. Reagent A included in the Mitochondrial isolation kit was added to the cells and mixed. Then, isolation reagent B was added and mixed. After that, the mixture was mixed at maximum speed per minute for 5 minutes at 4°C. Isolation reagent C was added, the tube was inverted, and centrifuged (700 g, 10 minutes) at 4°C.
  • the sediment was suspended in isolation reagent C and centrifuged at 4°C (12,000 g, 5 minutes) to obtain mitochondria.
  • the protein concentration of mitochondria was measured using BCA protein assay kit (Thermo Fisher Scientific, USA) using BSA (Bovine Serum Albumin) as a standard protein, and the results are shown in Figure 4.
  • Example 5-1 Induction and administration of animal models
  • Diabetes is a disease in which sugar is not absorbed into cells, and thus the cells cannot use sugar as a sufficient energy source.
  • This sugar absorption disorder is caused by decreased secretion of insulin or insulin resistance. Insulin is secreted from pancreatic cells, and sends a signal by binding to the insulin receptor on the cell membrane so that blood sugar can be absorbed into the cells, and this causes sugar metabolism and energy metabolism in each tissue to occur, so that blood sugar can be maintained at a constant level through metabolism in the body. If insulin secretion decreases due to decreased function of pancreatic beta cells, or insulin resistance in peripheral tissues such as muscles, liver, and blood vessels increases, blood sugar cannot be used as an energy source and is excreted from the body, which leads to various complications. Therefore, insulin secretion and sugar absorption can be monitored using an animal model in which diabetes is induced, and the animal model can analyze the mechanism by which absorbed sugar is converted into an energy source and then metabolized, so it was selected as the subject of this experiment.
  • mice 6-week-old male C57BL/6 mice were separated into groups of 6 each and acclimated for 1 week. Specifically, as shown in Table 2 below, a normal diet group (ND) group fed a normal diet (Zeigler Bros., USA) and a high-fat diet group (HFD) group fed a high-fat diet (Research Diets, USA) were prepared.
  • ND normal diet group
  • HFD high-fat diet group
  • T2D Type 2 diabetes
  • the sugars administered in addition to the diet were kestose, sucrose, or fructooligosaccharide (FOP).
  • the general diet administered to the above experimental animals was Rodent NIH-41 Open Formula Diet sold by Zeigler Bros., Inc., and its specific composition is shown in Table 3.
  • the high-fat diet was the product D12492 (Rodent Diet With 60 kcal% Fat) sold by Research Diets, Inc., and its specific composition is shown in Table 4.
  • the experimental animals used in this experiment were divided into negative control group, positive control group, comparison group, and test group (see Table 2).
  • Example 5-2 Measurement of mouse weight gain and food intake and collection of feces
  • Example 5-1 During the T2D induction and test group administration period of Example 5-1 above, the weight change of the mice according to each experimental group administration was recorded to measure the weight change according to T2D induction. The weight measurement for measuring the weight change was performed at the same time before oral administration every week.
  • Example 5-3 Analysis of the regulatory effects of sugar uptake and utilization factors and mitochondrial biogenesis promoting factors in mouse muscle tissue
  • mice whose weight changes were analyzed in Example 5-2 above were sacrificed, muscle tissues were obtained from the sacrificed mice, and RNA was extracted using an RNeasy mini kit (Qiagen, Germany). cDNA was synthesized using the RNA extracted from the muscle tissues using a cDNA synthesis kit (Takara, Japan).
  • AMPK, SIRT1, PGC1 ⁇ , NRF1, IRS-1, Akt, MyoD, and MyoG which are factors promoting mitochondrial biogenesis, showed higher expression levels in the groups treated with a normal diet, a high-fat diet, and 1-kestose compared to the other groups.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne : une composition pour améliorer le métabolisme énergétique cellulaire, comprenant du kestose en tant que principe actif ; et son utilisation pour la prévention, le traitement ou l'amélioration de maladies liées au métabolisme énergétique cellulaire.
PCT/KR2024/021115 2023-12-27 2024-12-26 Composition pour améliorer le métabolisme bioénergétique contenant du kestose Pending WO2025143788A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2023-0193292 2023-12-27
KR20230193292 2023-12-27

Publications (1)

Publication Number Publication Date
WO2025143788A1 true WO2025143788A1 (fr) 2025-07-03

Family

ID=96219372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2024/021115 Pending WO2025143788A1 (fr) 2023-12-27 2024-12-26 Composition pour améliorer le métabolisme bioénergétique contenant du kestose

Country Status (3)

Country Link
KR (1) KR20250103510A (fr)
TW (1) TW202535421A (fr)
WO (1) WO2025143788A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1878738A1 (fr) * 2005-04-21 2008-01-16 The Hokuren Federation Of Agricultural Cooperatives Composition supprimant les allergies, aliment supprimant les allergies et agent supprimant les allergies
US20090142304A1 (en) * 2005-10-13 2009-06-04 Koichiro Murashima Composition for Improving Intestinal Flora
KR20190131102A (ko) * 2017-03-31 2019-11-25 붓산 푸드사이언스 가부시키가이샤 인슐린 저항성의 악화예방 또는 개선제
KR20220097322A (ko) * 2020-12-31 2022-07-07 주식회사 삼양사 케스토스를 이용한 프로피온산 증진 용도

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1878738A1 (fr) * 2005-04-21 2008-01-16 The Hokuren Federation Of Agricultural Cooperatives Composition supprimant les allergies, aliment supprimant les allergies et agent supprimant les allergies
US20090142304A1 (en) * 2005-10-13 2009-06-04 Koichiro Murashima Composition for Improving Intestinal Flora
KR20190131102A (ko) * 2017-03-31 2019-11-25 붓산 푸드사이언스 가부시키가이샤 인슐린 저항성의 악화예방 또는 개선제
KR20220097322A (ko) * 2020-12-31 2022-07-07 주식회사 삼양사 케스토스를 이용한 프로피온산 증진 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WATANABE AYAKO, TOCHIO TAKUMI, KADOTA YOSHIHIRO, TAKAHASHI MOTOKI, KITAURA YASUYUKI, ISHIKAWA HIROHITO, YASUTAKE TAKANORI, NAKANO : "Supplementation of 1-Kestose Modulates the Gut Microbiota Composition to Ameliorate Glucose Metabolism in Obesity-Prone Hosts", NUTRIENTS, vol. 13, no. 9, CH , pages 2983 - 2983-14, XP093330868, ISSN: 2072-6643, DOI: 10.3390/nu13092983 *

Also Published As

Publication number Publication date
TW202535421A (zh) 2025-09-16
KR20250103510A (ko) 2025-07-07

Similar Documents

Publication Publication Date Title
EA006556B1 (ru) Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот
WO2021004919A1 (fr) Compositions et méthodes utilisant de la trigonelline et des vitamines pour la prévention ou le traitement d'affections ou de troubles des muscles squelettiques
WO2013081294A1 (fr) Agent d'augmentation de la concentration d'équol contenant du psicose comme principe actif
US20220241266A1 (en) Compositions and methods using trigonelline and high protein for preventing or treating conditions or disorders in skeletal muscle
WO2004075905A1 (fr) Agent de formation musculaire et agent de prevention et de soins en cas d'affaiblissement musculaire
WO2020040382A1 (fr) Nouveau composé de magnésium-sérinate et son utilisation
WO2025143788A1 (fr) Composition pour améliorer le métabolisme bioénergétique contenant du kestose
EP1690519A1 (fr) Inhibiteur de l'activite de l'alpha-glucosidase
KR102612548B1 (ko) 락토바실러스 부크너리 200793 균주를 포함하는 우울증예방, 개선 또는 치료용 조성물
WO2006136423A2 (fr) Nouvelle utilisation de composes organiques
CA3140733A1 (fr) Compositions et methodes utilisant de la trigonelline et des mineraux pour prevenir ou traiter des etats pathologiques ou des troubles du muscle squelettique
WO2023239016A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies métaboliques contenant du déméthylzeylastéral
JP2015193547A (ja) 運動様作用を有するレスベラトロール加熱処理組成物
Hoong Loo et al. Phenylketonuria and vitamin B6 function
WO2021177660A1 (fr) Composition de perte de poids comprenant des analogues de l'œnothéine b en tant que principe actif
WO2020235900A1 (fr) Utilisation d'une composition pour la prévention, l'amélioration ou le traitement de troubles de la perte osseuse, comprenant le cyclo-hispro (chp) et l'hormone parathyroïde
WO2020218148A1 (fr) Inhibiteur de production de peroxyde de lipides
KR20150131477A (ko) 설포라판 유도체를 유효성분으로 함유하는 당뇨병 예방 및 치료용 조성물
WO2014017741A1 (fr) Composition pharmaceutique contenant de la prunétine en tant que principe actif pour prévenir ou traiter l'obésité ou des maladies métaboliques
Ong et al. Anti-aging Interventions: Caloric Restriction and Beyond
JP7227962B2 (ja) 筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物
JP2025526605A (ja) Ｓｇｌｔ２阻害剤としてのメチル化フロレチン類似体
KR20240033706A (ko) 당뇨병 예방 또는 치료용 조성물
JP6374682B2 (ja) 筋萎縮抑制剤
WO2025249971A1 (fr) Composition comprenant de l'altiratinib comme principe actif pour la prévention ou le traitement de l'arthrite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24913395

Country of ref document: EP

Kind code of ref document: A1